# The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

> **NCT00279201** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2091 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin glargine
- **DRUG:** Lispro Low Mix
- **DRUG:** Lispro Mid Mix
- **DRUG:** Lispro

## Key facts

- **NCT ID:** NCT00279201
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 2091 (ACTUAL)
- **Last updated:** 2011-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279201, "The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00279201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*